Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial.
Background: Anemia secondary to iron deficiency is common in patients with non-dialysis dependent chronic kidney disease (ND-CKD) but it is unclear if oral supplementation is as effective as intravenous (IV) supplementation in re-establishing iron stores. The purpose of this study was to determine i...
| Publicado en: | BMC Nephrology Vol. 14; no. 1; pp. 64 - 65 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research randomized controlled trial Journal Article |
| Publicado: |
BioMed Central
2013
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104257220&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104257220 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 14712369 1CI6 jtl: BMC Nephrology issn: 14712369 maglogo: N pubinfo: dt: 2013 vid: 14 iid: 1 pid: 24147 pub: BioMed Central artinfo: ui: 104257220 104257220 NLM23514036 2012057455 10.1186/1471-2369-14-64 NLM23514036 PMC3606612 104257220 ppf: 64 ppct: 1 formats: tig: atl: Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial. aug: au: Nagaraju, Shankar P Cohn, Adam Akbari, Ayub Davis, Janet L Zimmerman, Deborah L affil: Department of Medicine, Division of Nephrology, Ottawa Hospital Research Institute, Ottawa, ON, Canada. dzimmerman@toh.on.ca. sug: subj: Anemia, Iron Deficiency Complications Anemia, Iron Deficiency Drug Therapy Iron Administration and Dosage Peptides Administration and Dosage Renal Insufficiency Complications Renal Insufficiency Drug Therapy Administration, Oral Aged Aged, 80 and Over Anemia, Iron Deficiency Diagnosis Dialysis Female Human Male Middle Age Renal Insufficiency Diagnosis Treatment Outcomes Randomized Controlled Trials Aged: 65+ years Aged, 80 & over Middle Aged: 45-64 years Female Male ab: Background: Anemia secondary to iron deficiency is common in patients with non-dialysis dependent chronic kidney disease (ND-CKD) but it is unclear if oral supplementation is as effective as intravenous (IV) supplementation in re-establishing iron stores. The purpose of this study was to determine if oral Heme Iron Polypeptide (HIP) is as effective as IV iron sucrose in the treatment of iron-deficiency anemia for patients with ND-CKD.Methods: Forty ND-CKD patients were randomized; 18 to HIP 11 mg orally 3 times per day and 22 to IV iron sucrose 200 mg monthly for 6 months. Baseline clinical and laboratory data were collected for all patients. The primary and secondary outcomes for the study were hemoglobin (Hgb) concentration and iron indices [ferritin and percentage transferrin saturation (TSAT)] at the end of 6 months respectively. Adverse events were also compared.Results: The baseline demographic characteristics and laboratory values were similar for the two groups. After 6 months of treatment, Hb in the HIP group was 117 g/L and 113 g/L in the IV sucrose group (p = 0.37). The TSAT at 6 months was not different between the two groups {p = 0.82}but the serum ferritin was significantly higher in the IV iron sucrose group {85.5 ug/L in HIP and 244 ug/L; p = 0.004}. Overall adverse events were not different between the groups.Conclusion: HIP is similar in efficacy to IV iron sucrose in maintaining hemoglobin in ND-CKD patients with no differences in adverse events over 6 months. It is unclear if the greater ferritin values in the IV iron sucrose group are clinically significant.Trial Registration: ClinicalTrials.gov: NCT00318812. pubtype: Academic Journal doctype: research randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|